Buck Wealth Strategies’s Idexx Laboratories IDXX Stock Holding History

Buck Wealth Strategies’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6	Closed	-$2.62K	–	183
2023 Q3	$2.62K	Hold	6	–	–	﹤0.01%	295
2023 Q2	$3.01K	Hold	6	–	–	﹤0.01%	218
2023 Q1	$3K	Buy	+6	New	+$2.87K	﹤0.01%	158

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Buck Wealth Strategies's IDXX Position: Q4 2023 in Review

Buck Wealth Strategies sold out of Idexx Laboratories (IDXX) in Q4 2023, closing a stake of 6 shares — an estimated $2.62K sold.

Buck Wealth Strategies first reported a position in IDXX in Q1 2023 and held it in 3 quarters. The position peaked at $3.01K in Q2 2023. 1,153 funds tracked by Wall St. Rank hold IDXX as of Q4 2023.

Buck Wealth Strategies reported no remaining Idexx Laboratories position as of Q4 2023 after selling out during the quarter.
Buck Wealth Strategies sold 6 Idexx Laboratories shares in Q4 2023, an estimated $2.62K.
Buck Wealth Strategies first reported a position in Idexx Laboratories in Q1 2023 and held it in 3 quarters.
Buck Wealth Strategies's Idexx Laboratories position peaked at $3.01K in Q2 2023.
1,153 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2023.

Based on Buck Wealth Strategies's 13F filing for Q4 2023, filed 23 Jan 2024.